SCHEMBL5056229

SCHEMBL5056229

O=C1NCCN1c1cccc(F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.50
HCRTR1 O43613 1/20 0.49
ALDH1A1 P00352 2/20 0.49
POLB P06746 2/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
FAAH O00519 1/20 0.49
MGLL Q99685 1/20 0.49
DRD2 P14416 1/20 0.47
DRD3 P35462 1/20 0.47
FADS1 O60427 1/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SCN9A Q15858 1/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965858 0.82 DDB1 (0.61) ALOX5HCRTR1ALDH1A1MAPTDRD2
SCHEMBL7344849 0.82 ALOX5 (0.59) ALOX5ALDH1A1MAPTMGLLDRD2
SCHEMBL1787047 0.81 ALDH1A1 (0.51) ALOX5ALDH1A1MGLLMEN1KMT2A
SCHEMBL150081 0.81 ALOX5 (0.60) ALOX5POLBMAPTMGLLDRD2
SCHEMBL4679705 0.81 GPR6 (0.46) ALOX5ALDH1A1POLBGAAMAPT
SCHEMBL5182221 0.81 FAAH (0.47) ALOX5HCRTR1POLBMAPTFAAH
SCHEMBL13737111 0.80 ALDH1A1 (0.56) ALOX5ALDH1A1GAAMAPTDRD2
SCHEMBL27945523 0.79 HTR1A (0.54) ALOX5ALDH1A1FAAHMGLLDRD2
SCHEMBL146714 0.79 NPC1 (0.56) ALOX5ALDH1A1POLBGAAMAPT
SCHEMBL5604528 0.78 ADRB1 (0.55) ALOX5MAPTMGLLDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288589-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-09-18 US disclosed
EP-4444289-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
US-20240208964-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE YUMANITY THERAPEUTICS, INC. 2024-06-27 US disclosed
US-20240208964-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE YUMANITY THERAPEUTICS, INC. 2024-06-27 US disclosed
WO-2023107592-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107592-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
EP-4161926-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Yumanity Therapeutics, Inc. (US) 2023-04-12 EP disclosed
WO-2008035209-A2 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-27 WO disclosed
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity METHYLGENE, INC. (CA) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208964-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE PNPO, DPYD, PYGB ALOX5 980/4885HCRTR1 3087/4885ALDH1A1 945/4885
US-20250288589-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE PNPO, DPYD, PYGB ALOX5 980/4885HCRTR1 3087/4885ALDH1A1 945/4885
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity HGF, ERBB2, MET ALOX5 3609/4885HCRTR1 3823/4885ALDH1A1 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.